Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
St. Anna Kinderkrebsforschung
Roswell Park Cancer Institute
Hebei Senlang Biotechnology Inc., Ltd.
Peking University People's Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
The Royal Bournemouth Hospital
Roswell Park Cancer Institute